Serevent Shortage: What Providers and Prescribers Need to Know in 2026

Serevent Diskus (salmeterol xinafoate) is not on the FDA's official drug shortage list in 2026, but your patients may still report difficulty filling it. This briefing covers the current availability landscape, the clinical and formulary implications of the AirDuo RespiClick discontinuation, common insurance access barriers, and practical strategies for managing affected patients.

Supply Status: Serevent Diskus vs. AirDuo RespiClick

Two distinct salmeterol-containing products are relevant to this discussion:

Serevent Diskus (GSK): Salmeterol 50 mcg standalone DPI. Not in FDA shortage. Generally available through wholesale, though pharmacy-level stock gaps occur due to inconsistent ordering of this specialty brand.

AirDuo RespiClick (Teva): Fluticasone/salmeterol combination MDI. Discontinued by Teva in all presentations. Patients on AirDuo must be transitioned to alternative therapy.

Patients transitioning from AirDuo to another fluticasone/salmeterol option (e.g., Wixela Inhub) should be counseled on device technique differences between the RespiClick MDI and the Diskus DPI.

The Real Access Barrier: Brand-Only Status and Insurance Restrictions

The primary obstacle for Serevent patients in 2026 is not supply — it is cost and formulary placement. No generic version of salmeterol exists as a standalone inhaler in the U.S. as of 2026, which means:

Retail cash price: $420–$557 per 60-inhalation inhaler

Insurance tier: Typically Tier 3 (non-preferred brand) on most commercial formularies

Prior authorization: Often required; many plans cite "therapeutic alternative available" when standalone ICS/LABA combinations exist

Step therapy: Some plans require a trial of a combination ICS/LABA (like generic fluticasone/salmeterol or budesonide/formoterol) before approving standalone salmeterol

Clinical Rationale for Standalone Salmeterol

When prior authorization or step therapy requirements arise, be prepared to document clinical rationale for standalone salmeterol. Appropriate scenarios include:

COPD patients who do not require ICS and for whom a standalone LABA is the preferred approach (avoiding unnecessary ICS exposure and its associated risks)

Asthma patients already optimized on a specific ICS that is not available in a fixed-dose combination with salmeterol

Patients requiring individualized dosing of ICS and LABA components that cannot be achieved with fixed-dose combinations

Prevention of exercise-induced bronchospasm (EIB) where a standalone LABA used intermittently is clinically appropriate

Therapeutic Alternatives by Indication

If Serevent is not accessible for a patient, consider the following formulary-friendly alternatives:

Asthma (ICS required): Wixela Inhub (generic fluticasone/salmeterol) or generic budesonide/formoterol. The former contains the same LABA; the latter offers fastest access at lowest cost. Dose equivalency should guide ICS selection.

COPD (LABA only): Formoterol (Foradil) as standalone twice-daily LABA; or once-daily indacaterol (Arcapta) or olodaterol (Striverdi) for patients who benefit from once-daily dosing and improved adherence.

COPD (combination therapy): Generic budesonide/formoterol or Breo Ellipta (once-daily ICS/LABA). For LABA/LAMA combinations: Stiolto Respimat (olodaterol/tiotropium) or Bevespi Aerosphere.

Savings Options to Share With Patients

If you decide to continue prescribing Serevent Diskus, direct patients to these programs:

GSK 'Pay No More Than $35' coupon: For commercially insured patients. Patients must be on a commercial plan with no government insurance (Medicare, Medicaid, TRICARE) to qualify.

GSK Access Patient Assistance Program: For uninsured or underinsured patients who meet income criteria. Medication may be provided at no cost. Call 1-866-728-4368 or visit gsk-access.com.

GoodRx / SingleCare: Discount cards offering prices in the $378–$406 range. Not as good as the $35 copay card for commercially insured patients, but useful for uninsured patients who don't qualify for PAP.

Helping Patients Find a Stocked Pharmacy

When patients can't find Serevent at their local pharmacy, direct them to medfinder for Providers. medfinder calls pharmacies near the patient to find which ones can fill the prescription, then texts results to the patient — eliminating the need for patients to call pharmacies themselves.

Black Box Warning: Clinical Reminders

When prescribing Serevent for asthma, ensure the following are documented and communicated to patients:

Serevent must always be used concurrently with an ICS in asthma — never as monotherapy

The SMART trial demonstrated increased asthma-related mortality with salmeterol monotherapy (13 vs. 3 deaths per 13,000+ patients over 28 weeks)

Serevent is not a rescue inhaler — patients must have a SABA (e.g., albuterol) for acute symptoms

Do not use Serevent concurrently with other LABAs or with strong CYP3A4 inhibitors (HIV protease inhibitors, cobicistat)

Summary Recommendations for Providers

Consider whether a combination ICS/LABA (especially generic Wixela or generic budesonide/formoterol) would be clinically equivalent and more formulary-accessible for your patient. When Serevent is clinically indicated, document the specific clinical rationale to support prior authorization. For more detailed guidance on helping your patients access Serevent, see: How to Help Your Patients Find Serevent in Stock.